natgillin/translations-raw huggingface dataset:
The compounds according to the present invention are described by the following formula (I) where: 
Spojevi prema ovom izumu opisani su slijedećom formulom (I) gdje:
The extended release dosage form of any one of claims 1 to 22, wherein the opioid analgesic is selected from the group of codeine, morphine, oxycodone, hydrocodone, hydromorphone, or oxymorphone or pharmaceutically acceptable salts, hydrates and solvates thereof, mixtures of any of the foregoing. 
Oblik za doziranje s produljenim otpuštanjem prema zahtjevu 13, naznačen time da je opioidni analgetik odabran iz skupine kodeina, morfina, oksikodona, hidrokodona, hidromorfona, ili oksimorfona ili njihovih farmaceutski prihvatljivih soli, hidrata ili solvata, smjese bilo kojeg od prethodno navedenih.
the heavy chain constant region is a modified or unmodified IgG, IgM, IgA, IgD, IgE, a fragment thereof, or combinations thereof, optionally wherein the heavy chain constant region is a modified or unmodified IgG1, IgG2, IgG3 or IgG4; 
Antitijelo prema bilo kojem od prethodnih Patentnih zahtjeva, naznačeno time, što konstantna regija teškog lanca predstavlja izmijenjen ili neizmijenjen IgG, IgM, IgA, IgD, IgE, njihov fragment ili njihove kombinacije. Antitijelo Patentnog zahtjeva 4, naznačeno time, što konstantna regija teškog lanca predstavlja izmijenjen ili neizmjenjen IgG1, IgG2, IgG3 ili IgG4.
and wherein said alkyl, alkenyl, alkynyl and aliphatic groups are the same or different and are each unsubstituted or substituted with 1, 2 or 3 unsubstituted substituents which are the same or different and are selected from halogen atoms and C1-C4 alkoxy, alkenyloxy, haloalkyl, C2-C4 haloalkenyl, C1-C4 haloalkoxy, C2-C4 haloalkenyloxy, hydroxyl, —SR′, and —NR′R″ groups where R′ and R″ are the same or different and represent hydrogen or unsubstituted C1-C2 alkyl; 
spomenute alkil, alkenil, alkinil i alifatske skupine su iste ili različite i svaka od njih je nesupstituirana ili supstituirana s 1, 2 ili 3 nesupstituirana supstituenta koji su isti ili različiti i odabrani su od atoma halogena i sljedećih skupina: C,-C,-alkoksi, C,-Cy-alkeniloksi, C;-Cy-haloalkil, C»-Cy-haloalkenil, Cy-Cy-haloalkoksi, C>- Cy-haloalkeniloksi, hidroksil, -SR', i -NR'R", gdje su R' i R" isti ili različiti te predstavljaju vodik ili nesupstituirani C,-C>2-alkil;
The invention also relates to the use of a plant strengthener as claimed in any of the preceding claims for increasing the tolerance of crop plants to stress events, in particular to chemically induced stress, cold-induced stress, drought-induced stress or light-induced stress. 
Postupak upotrebe osnaživača bilja prema bilo kojem od prethodnih zahtjeva naznačen time da pojačava toleranciju usjeva biljaka na stresne događaje, a osobito na kemijski inducirani stres, stres induciran hladnoćom, stres induciran sušom ili stres induciran svjetlom.
The compound or salt of claim 6, wherein the salt is chloride, bromide, iodide, sulfate, bisulfate, sulfamate, nitrate, phosphate, citrate, methanesulfonate, trifluoroacetate, glutamate, glucuronate, glutarate, malate, maleate, succinate, fumarate, tartrate, tosylate, salicylate, lactate, naphthalenesulfonate, or acetate. 
Spoj prema bilo kojem od prethodnih Zahtjeva 1 do 3, naznačen time, što spomenuta sol predstavlja klorid, bromid, jodid, sulfat, bisulfat, sulfamat, nitrat, fosfat, citrat, metansulfonat, trifluoroacetat, glutamat, glukuronat, glutarat, malat, maleat, sukcinat, fumarat, tartrat, tozilat, salicilat, laktat, naftalinesulfonat ili acetat.
The method of claims 8 or 9 wherein the herbicidally active components are applied pre-emergently or post-emergently. 
Postupak u skladu s patentnih zahtjeva 8 ili 9, naznačen time što se herbicidno aktivne komponente primjenjuje prije nicanja ili nakon nicanja.
The computer program product of any one of claims 11 to 14, further comprising increasing the mobile phone account of the user (102) to include a balance for payment of goods or services from a merchant. 
Proizvod računalni program prema bilo kojem od zahtjeva 9 do 11, dalje sadržeći povećanje računa mobilnog telefona korisnika (102) da uključuje saldo za plaćanje roba 1li usluga (105) od trgovca (104).
The isolated monoclonal antibody or antigen binding fragment of claim 1, wherein the light chain variable region comprises the amino acid sequence set forth as SEQ ID NO: 31. 
Protutijelo ili njegov za antigen vezni fragment prema zahtjevu 8, gdje varijabilni laki lanac obuhvaća SEQ ID NO:31.
a moiety of the formula: 
ostatka formule: [image] [image]
The message controller as claimed in claim 1, wherein the fresh response includes a false address to cause the message to be sent to a smart services control node, and wherein said node is the message controller or a different network element such as a different message controller. 
Kontroler poruka prema bilo kojem od prethodnih zahtjeva, pri čemu novo konstruirani odgovor sadrži lažnu adresu kako bi se dovelo do toga da se poruka pošalje ka kontrolnom čvoru za pametne servise, pri čemu je navedeni čvor kontroler poruka ili neki različiti mrežni element poput drugog kontrolera poruka.
The present invention further relates to activated cytotoxic T lymphocytes (CTL), produced by the method described, which selectively recognise a cell which aberrantly expresses a polypeptide comprising an amino acid sequence described. 
Aktivirani citotoksični T-limfocit (CTL), proizveden metodom u skladu s patentnim zahtjevom 9 ili 10, koji selektivno prepoznaje peptid u skladu sa zahtjevom 1 ili 2.
The process of claim 3, wherein said inorganic base is selected from the group consisting of LiOH, KOH, NaOH, Ca(OH)2, Li2CO3, Na2CO3, K2CO3, and Cs2CO3. 
Postupak u skladu s patentnim zahtjevom 14, naznačen time što navedenu anorgansku bazu se bira iz skupine koju čine LiOH, KOH, NaOH, Ca(OH),, L2C0,, NaC0g, K2CO; 1 Cs&COs.
Butyl-, octyl- or phenyl-sepharose (agarose) are further examples of such HIC resins. 
Butil, oktil ili fenil-sefaroza (agaroza) su daljnji primjeri za takve HIC nosače.
secondary phases 0 to 30 wt %, preferably 5 to 25 wt % and more preferably from 10 to 20 wt %. 
* sekundarne faze 0 do 30 mas %, pri čemu je x broj od 0.1 do 1, ohlađen.
The method of claim 13, wherein the size of the insertion or replacement is from about 5 kb to about 10 kb, from about 10 kb to about 20 kb, from about 20 kb to about 40 kb, from about 40 kb to about 60 kb, from about 60 kb to about 80 kb, from about 80 kb to about 100 kb, from about 100 kb to about 150 kb, from about 150 kb to about 200 kb, from about 200 kb to about 250 kb, from about 250 kb to about 300 kb, from about 300 kb to about 350 kb, or from about 350 kb to about 400 kb. 
Postupak sukladno patentnom zahtjevu 13, naznačen time, da je veličina umetanja ili zamjene od oko 5 kb do oko 10 kb, od oko 10 kb do oko 20 kb, od oko 20 kb do oko 40 kb, od oko 40 kb do oko 60 kb, od oko 60 kb do oko 80 kb, od oko 80 kb do oko 100 kb, od oko 100 kb do oko 150 kb, od oko 150 kb do oko 200 kb, od oko 200 kb do oko 250 kb, od oko 250 kb do oko 300 kb, od oko 300 kb do oko 350 kb ili od oko 350 kb do oko 400 kb.
The system of claim 14, wherein a single transparent member comprises a wall of the plurality of transparent walls and the transparent floor. 
Sustav iz zahtjeva 14, naznačen time da pojedinačan transparentan element (112) čini zid iz množine transparentnih zidova (112) i transparentni pod (116).
A compound having formula IV: wherein 
Spoj, naznačen time, da ima formulu IV: u čemu
Accordingly, in one embodiment the invention relates to a capsule for preparing a beverage by injection of a fluid, comprising a closed chamber and a means for allowing the said beverage to flow out, the closed chamber of said capsule comprising ground green coffee beans that has been heat treated at a temperature between 100°C and 180°C for at least 5 minutes keeping the moisture level between 6% and 20% of the total weight of the coffee beans, wherein the green coffee beans have not been subjected to roasting. 
HR P20131177 TI PATENTNI ZAHTJEVI Postupak dobivanja ekstrakta kave, koji se sastoji u: a) toplinskoj obradi sirovih zrna kave na temperaturi između 100 *C 1 180 *C u trajanju od najmanje 5 minuta, uz održavanje razine vlage između 6% i 20% od ukupne težine zrna kave; i b) ekstrahiranju obrađenih zrna kave iz koraka a) kako bi se dobilo tekući ekstrakt kave; naznačen time što se zrna kave i/ili ekstrakt kave ne podvrgava prženju.
A conjugate comprising an antibody of any one of claims 1-9 coupled to a therapeutic agent, preferably a toxin, a radioisotope, a drug or a cytotoxic agent. 
Konjugat koji sadrži antitijelo iz bilo kojeg od patentnih zahtjeva 1-9 koje je vezano za terapijski agens, poželjno toksin, radioizotop, lijek ili citotoksični agens.
a pH-adjusting agent in an amount sufficient to cause the composition to have a pH of 3.6 - 3.8; 
sredstva za podešavanje pH i količini dovoljnoj da pripravak ima pH od 3,6-3,8;
Metabolic Activation 
S9 Metabolička aktivacija
Dosage form according to any of the preceding embodiments, wherein the dosage form is selected from the group of dosage forms comprising a nasal spray, a nasal mucoadhesive dosage form and a Mucosal Atomizer Device. 
Oblik doziranja prema bilo kojem od prethodnih zahtjeva, naznačen time da je oblik doziranja odabran iz skupine oblika doziranja koji obuhvaćaju nazalni sprej, nazalni mukoadhezivni oblik doziranja 1 mukozni uređaj za atomiziranje.
separating the cathode material particles from the particulate cathode in a separation device comprising more than one sieve for providing recycled cathode material; wherein the transfer to the separation device is facilitated by a rotary feeder. 
(iv) odvajanje čestica katodnog materijala od usitnjenih čestica katode u uređaju za odvajanje koji sadržava više od jednog sita kako bi se dobio reciklirani katodni materijal; pri čemu je prijenos na uređaj za odvajanje olakšan pomoću rotacijskog dodavača.
wherein the flexible tip member is partially disposed within the sleeve, such that the distal end of the flexible tip member extends distally through the opening in the distal end of the sleeve, and the proximal end of the flexible tip member is disposed within the sleeve and between the proximal and distal ends of the sleeve, thereby being adapted to position the flexible tip member near the light source. The device of claim 1, wherein the flexible fiber optic tip member is unitarily formed. 
gdje vršni element fleksibilnog optičkog vlakna se dijelom nalazi u tuljcu, tako da udaljeni kraj vršnog elementa fleksibilnog optičkog vlakna se pruža distalno kroz otvor u udaljeni kraj tuljca, a bliski kraj vršnog elementa fleksibilnog optičkog vlakna se nalazi u tuljcu i između bliskog i udaljenog kraja tuljca, čime je konfiguriran za smještavanje vršnog elementa fleksibilnog optičkog vlakna blizu izvora svjetla.
the antibody or fragment is a single chain antibody, an Fab, or an F(ab')2; and/or the antibody or fragment is a chimeric or fully human antibody or antibody fragment. 
(a) -antitijelo ili fragment je jednolančano antitijelo, Fab ili F(ab'),; i/ili (b) antitijelo ili fragment je kimerno ili potpuno humano antitijelo ili fragment antitijela.
The insulin conjugate according to claim 12, wherein the succinimide derivative is succinimidyl propionate, succinimidyl carboxymethyl, hydroxy succinimidyl, or succinimidyl carbonate. 
Konjugat inzulina prema patentnom zahtjevu 12, naznačen time što sukcinimidni derivat je sukcinimidil propionat, sukcinimidil karboksimetil, hidroksi sukcinimidil ili sukcinimidil karbonat.
A pharmaceutical composition comprising the antibody of any one of items 1-19 and/or a conjugate of item 20 or 21, and a pharmaceutically acceptable carrier. 
Farmaceutska kompozicija koja sadrži antitijelo suglasno bilo kojem od zahtjeva 1-11 i/ili neki konjugat suglasno zahtjevu 12, kao i neki farmaceutski poželjni nosač.
Use of a compound according to claim 26 wherein the circadian rhythm sleep disorder is selected from the group consisting of shift work sleep disorder, jet lag syndrome, advanced sleep phase syndrome and delayed sleep phase syndrome. A process for the preparation of a compound of formula (I) wherein: 
Upotreba spoja u skladu s patentnim zahtjevom 26, gdje poremećaj cirkadijanog ritma spavanja se bira iz skupine koju čine poremećaj spavanja zbog smjenskog rada, poremećaj spavanja zbog promjene vremenske zone, poremećaj spavanja zbog pomaknute faze spavanja, poremećaj spavanja zbog odgođene faze spavanja.
A composition suitable for control of diseases caused by phytopathogens comprising (A) a compound of formula I 
PATENTNI ZAHTJEVI L wo ll. Pripravak pogodan za kontrolu bolesti uzrokovanih fitopatogenima koji se sastoji od:
In addition, the present invention also provides for the use of the compounds of the invention in combination with other active agents such as those belonging to the class of a-glucosidase inhibitors, aldose reductase inhibitors, biguanides, HMG-CoA reductase inhibitors, squalene synthesis inhibitors, fibrates, LDL catabolism enhancers, angiotensin converting enzyme (ACE) inhibitors, insulin secretion enhancers, thiazolidinedione and the like. 
Prikazani izum se također odnosi na uporabu spojeva prema izumu u kombinaciji s ostalim aktivnim sredstvima poput onih koja pripadaju inhibitorima a-glukozidaze, inhibitorima aldoza reduktaze, bigvanidima, HMG-CoA reduktaza inhibitorima, inhibitorima sinteze skvalena, fibratima, LDL katabolizam poboljšivačima, angiotenzin konvertaza inhibitorima (ACE), poboljšivačima sekrecije inzulina, tiazolidindionima i slično. Podloga izuma
The solid form of claim 23, characterized by three or more peaks expressed in 2-theta±0.2 at about 8.9, 14.8, 16.5, 18.6, 20.9, 22.2, and 23.4 degrees in an X-ray powder diffraction pattern obtained using Cu K alpha radiation. 
ii) koji se odlikuje s jednim ili više vrhova izraženim u 2-theta ± 0,2 na oko 8,9; 14,8; 16,5; 18,6; 20,9; 22,2 i 23,4 stupnjeva u rendgenskom difrakcijskom prahu dobivenom primjenom Cu K alfa zračenja; i/ili iii) koji se odlikuje time da ima rendgenski difrakcijski prah u osnovi isti kao onaj prikazan na Slici 1g;
and R14 may be bonded to form a 4- to 7-membered heterocycle optionally containing an additional element(s) or group(s) independently selected from O, N, S, SO and SO2, and the heterocycle optionally contains carbonyl, and the heterocycle is optionally substituted with C1-C10 alkyl; is selected from: 
i R14 mogu biti međusobno vezani kako bi tvorili 4- do 7-eročlani heterocikl koji izborno sadrži jedan ili više dodatnih elemenata ili jednu ili više skupina koji se neovisno biraju između O, N, S, SO i SO2, gdje heterocikl izborno sadrži karbonil, gdje je heterocikl izborno supstituiran s C1-C10 alkilom;
In one particular embodiment, the final concentration of the succinate buffer is 5 mM. In other embodiments, the salt in the pH buffered saline solution comprises magnesium chloride, potassium chloride, sodium chloride or a combination thereof. In one particular embodiment, the salt in the pH buffered saline solution is sodium chloride. 
Formulacija u skladu s bilo kojim od patentnih zahtjeva 1 do 5, naznačena time što sol u fiziološkoj otopini s puferiranim pH sadrži magnezijev klorid, kalijev klorid, natrijev klorid ili njihovu kombinaciju. Formulacija u skladu s patentnim zahtjevom 6, naznačena time što je sol u fiziološkoj otopini s puferiranim pH natrijev klorid.
The invention includes all tautomeric forms of the compounds. 
Izum obuhvaća sve tautomerne oblike spojeva.
The far infrared anion complex sanitary napkin/pad according to Claim 8, wherein the Chinese herbal essential layer is located at the central portion of the sanitary napkin/pad, and the ratio of the length and the width of the Chinese herbal essential layer with respect to the length and the width of the sanitary napkin/pad is in a range of 1/2 to 2/3. 
Higijenski uložak/jastučić dalekog infracrvenog anionskog kompleksa prema zahtjevu 8, gdje se sloj s esencijom kineskih biljaka nalazi u središnjem dijelu higijenskog uloška/jastučića, i omjer duljine 1 širine sloja sloj s esencijom kineskih biljaka u odnosu na duljinu 1 širinu higijenskog uloška/jastučića je u rasponu od 1/2 do 2/3.
The deprotection according to method 10 can be performed as described in method 9. 
Deprotekcija u skladu s metodom 10 može se vršiti na način kako je to opisano u metodi 9.
The solid form for use according to claim 9 wherein the disease or condition mediated by vasopressin V2 receptors is selected from nocturnal enuresis, nocturia, polyuria resulting from central diabetes insipidus, urinary incontinence and bleeding disorders. 
Čvrsti oblik za upotrebu prema zahtjevu 9, naznačen time što je oboljenje ili stanje posredovano vazopresin V> receptorima izabrano između noćnog mokrenja, nokturije, poliurije uslijed centralnog dijabetesa insipidusa, urinarne inkontinencije 1 poremećaja krvarenja.
The method as claimed in claim 1, wherein the alert signal is outputted to an alert device which is remote of the inductance sensing circuit installation. 
Metoda kao što je navedeno u bilo kojem od zahtjeva 1 do 4, pri čemu se signal upozorenja šalje uređaju za upozorenje koji je udaljen od instalacije strujnog kruga za očitavanje induktiviteta (12).
The pharmaceutical composition of claim 1 or 2, wherein the (3R)-quinuclidin-3-yl (1S)-1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylate or a pharmaceutically acceptable salt thereof is (3R)-quinuclidin-3-yl (1S)-1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylate succinate. 
Farmaceutski sastav prema zahljevu 1 ili 2, naznačen time, da (3R)-kinuklidin-3-11((1S)-1-fenil-1,2,3,4-tetrahidroizokinolin-2-karboksilat ili njegova farmaceutski prihvatljiva sol je (3R)-kinuklidin-3-1(15)-1-fenil-1,2,3,4-tetrahidroizokinolin-2-karboksilat sukcinat.
Cortexolone-17a-propionate in crystalline form I according to claim 12 or 13 for use in treating pathologies affecting the urogenital system, the endocrine system, the skin and/or the cutaneous appendages. 
Korteksolon-17a-propionat u kristalnom obliku III u skladu s bilo kojim od patentnih zahtjeva 15 do 18, naznačen time što je namijenjen upotrebi u liječenju patoloških pojava koje pogađaju urogenitalni sustav, endokrini sustav, kožu i/ili derivate kože.
A process for the preparation of compounds of formula (I) according to claim 1 or pharmaceutically usable solvates or salts thereof, comprising reacting a compound of formula (II) 
Postupak za dobivanje spojeva formule (I) prema zahtjevima 1-11 1 njegovih solvata, soli i stereoizomera, naznačen time da spoj formule (II)
The process according to claim 1, wherein compound II, compound III and compound IV are mixed together at the start of the process. 
Postupak prema zahtjevu 12, gdje se spoj II, spoj III i spoj IV miješaju zajedno na početku postupka.
Engelmann, H., Novick, D. and Wallach, D. 
Engelmann, H., Novick, D. i Wallach, D.
Ring B is wherein R4a is a phenyl group substituted by a halogen atom, a cyano group, an alkyl group, a haloalkyl group, an alkoxy group, a haloalkoxy group, an alkylenedioxy group, an alkyleneoxy group, or a mono- or di-alkylamino group; or a heterocyclyl group substituted by a halogen atom, a cyano group, an alkyl group, a haloalkyl group, an alkoxy group or a haloalkoxy group, and R5a is a hydrogen atom; 
Prsten B je [image], gdje R4a je fenilna skupina, supstituirana s atomom halogena, cijano skupinom, alkilnom skupinom, halogenalkilnom skupinom, alkoksi skupinom, halogenalkoksi skupinom, alkilendioksi skupinom, alkilenoksi skupinom ili mono- ili di-alkilamino skupinom; ili heterociklilna skupina, supstituirana s atomom halogena, cijano skupinom, alkilnom skupinom, halogenalkilnom skupinom, alkoksi skupinom ili halogenalkoksi skupinom; a R5a je atom vodika;
WO 97/46527 describes a method for the preparation of the polymorphic forms I to V and of the amorphous form of do-nepezil hydrochloride. 
U WO 97/46527 opisan je postupak pripreme polimorfnih oblika I do V i amorfnih oblika donepezil hidroklorida.
Method according to claim 11 or 12, wherein a high-pass filter is applied to the acceleration signal before step b). 
Metoda prema zahtjevu 11 1li 12, pri čemu se visokopropusni filtar primjenjuje na signal ubrzanja prije koraka b).
There is thus provided in accordance with an embodiment of the present invention a key blank including a generally elongate shaft portion defining first and second generally flat oppositely directed side surfaces, joined by edge surfaces, at least one of the first and second side surfaces cuttable to form key cuts that define a key combination surface, and at least one key combination element (e.g., a spring) movably disposed in the elongate shaft portion and adapted for touching a lock combination element disposed in a cylinder lock plug, wherein the at least one key combination element has inherent energy for applying an urging force against the lock combination element. 
WO-A-00/57006 opisuje prazan ključ koji ima općenito izduženi trupni dio s dvije ravne površine (prvom i drugom) okrenute na suprotne strane i spojene rubnim površinama, pri čemu se barem jedna od spomenute dvije ravne površine može urezati tako da nastanu urezi ključa koji određuju površinu kombinacije ključa; i barem jedan pokretni element kombinacije ključa u izduženom trupnom dijelu ključa koji je podešen tako da dolazi u doticaj s elementom kombinacije brave u zatvaraču cilindrične brave, pri čemu barem jedan element kombinacije ključa može svojom energijom prenijeti silu na element kombinacije brave.
A process for preparing an oxycodone hydrochloride composition having a 14-hydroxycodeinone level in an amount of less than 25 ppm as determined by the HPLC method of Example 6, comprising reacting in a suitable solvent an oxycodone base composition having an amount of 8,14-dihydroxy-7,8-dihydrocodeinone with hydrochloric acid in an amount greater than 1.0 molar equivalent as compared to the oxycodone base composition, whereby the 8,14-dihydroxy-7,8-dihydrocodeinone is dehydrated to 14-hydroxycodeinone, and under reducing conditions provided by a catalyst and a hydrogen donor, whereby 14-hydroxycodeinone is converted to oxycodone, wherein the solvent is selected from the group consisting of water, an alcohol, an ether, an amide, N-methylpyrrolidone, a carboxylic acid, and an appropriate mixture of any two or more of the aforementioned solvents. 
Farmaceutski oblik doziranja prema bilo kojem patentnom zahtjevu od 1 do 8, naznačen time da je donji limit 14-hidroksikodeinona 5 ppm, 2 ppm, 1 ppm, 0.5 ppm ili 0.25 ppm. Farmaceutski oblik doziranja prema bilo kojem patentnom zahtjevu od 1 do 10, naznačen time da se može dobiti postupkom koji sadrži korake reakciju sastava baze oksikodona koji sadrži 8,14-dihidroksi-7,8-dihidrokodeinon s klorovodičnom kiselinom, gdje je 8,14-dihidroksi-7,8-dihidrokodeinon is dehidriran u 14-hidroksikodeinon tijekom dobivanja soli, i u redukcijskim uvjetima tako da se 14-hidroksikodeinon prevede u oksikodon, dobivajući tako sastav oksikodon hidroklorida koji ima razinu 14-hidroksikodeinona manju od 25 ppm, i
precipitating proteins from a cryo-poor plasma fraction, in a first precipitation step, with between about 6% and about 10% alcohol at a pH of between about 7.0 and about 7.5 to obtain a first precipitate and a first supernatant; 
taloženje kriosiromašne frakcije plazme, u prvom koraku taloženja, s oko 6% do oko 10% alkohola uz pH-vrijednost između oko 7,0 i oko 7,5, za dobivanje prvog taloga i prvoga dijela koji pliva na površini;